Shots:

• South Korea's FTC has approved Danaher’s $21.4 billion acquisition of GE biopharma on condition that the companies will sell eight bioprocessing product assets addressing monopoly concerns
• The FTC’s approval follows EU’s conditional approval received in Dec 2019 after it agrees to sell five businesses to address worries about competition
• In Feb’2019- Danaher announced the acquisition of biopharma business of GE Life Sciences in all-cash transaction making a deal value ~$21.4B

Click here to read full press release/ article | Ref: Reuters | Image: Signbox